New CEO appointed

The global company Biosynth, headquartered in Staad (CH), has appointed Matt Gunnison as CEO and Kieran Murphy as Chairman.

In November, Biosynth announced that the Board of Directors has appointed Matt Gunnison as the company’s new Chief Executive Officer (CEO) and as a member of the Board of Directors. The Board has also appointed Kieran Murphy as Chairman with effect from the same date.

Matt Gunnison succeeds Urs Spitz, who remains a member of the Board of Directors. Gunnison joins from life science investment platform Gamma Biosciences, which he co-founded with investment firm KKR. He has nearly two decades of experience in the healthcare and life sciences industry. As Gamma’s CEO, he oversaw the acquisition and management of a portfolio of growth companies operating in the biopharmaceutical industry. Prior to Gamma, he held various positions at GE Healthcare. He holds a B.A. in Economics from Georgetown University and a J.D. from the University of Michigan.

Kieran Murphy was a Senior Advisor at KKR and joined Biosynth from Gamma Biosciences, where he has served as Chairman since 2022. He has decades of corporate leadership and board experience in the healthcare and life sciences industries, including as former President and CEO of GE Healthcare and GE Healthcare Life Sciences.